Nano Approaches to Modulate Host Cell Response for Cancer Therapy
The University of North Carolina at Chapel Hill
Host response targeting of both immune and stromal components represents an enormous opportunity to overcome cancer through the body's built in defense mechanisms. The focus of the UNC-Chapel Hill CCNE is to exploit the host response through nano approaches for cancer disease management and treatment. The research team is led by Principal Investigators Leaf Huang, Ph.D. and Joel Tepper, M.D. Leaf Huang is a pioneer in liposome research and non-viral gene therapy. He was the first a) to publish grafting polyethylene glycol to liposomes to enhance the circulation time; and b) to develop a low toxicity cationic lipid for gene transfection. Joel Tepper, M.D. is an accomplished leader and clinical and translational investigator who has contributed at both the local and national level to translational research and was co-PI of the previous UNC CCNE. The Center proposes developing targeted methods for the delivery of biologics and immunologic modifiers and chemotherapies against melanoma and non-small cell lung cancers (NSCLC), utilizing innovative nanotechnologies developed at UNC. There are four projects in the CCNE. The projects revolve around the central theme of exploiting the host response against tumors with an emphasis on the immune response. Center projects emphasize the treatment of malignant melanoma, an aggressive tumor with a strong immunological component, and NSCLC, a tumor that when advanced is not well treated by most therapeutic modalities.
- Project 1: Nanotherapies for Vemurafenib Resistant Melanoma
- Project 2: Nanoparticle-based Immune Modulators in Cancer Therapy and Vaccines
- Project 3: Combining Radiotherapy and Nanotechnology for Immunotherapy
- Project 4: High Capacity Polymeric Micelle Therapeutics for Lung Cancer